- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01907009
A Phase II Study Evaluating Intravenous Melphalan With Autologous Whole Blood Stem Cell Transplantation Over Three Cycles In Patients With Castration-Resistant Prostate Cancer (MEL-CAP) (MEL-CAP)
The management of (castration-resistant) prostate cancer (CRPC) is becoming increasingly complex. The use of peripheral anti-androgens with gonadorelin analogues (maximum androgen blockade) is common place. Following the failure of such an approach, several strategies may be employed. Both corticosteroids and estrogens have a role and increasingly chemotherapy is being used. The demonstration of enhanced survival using 3 weekly docetaxel has meant that this is viewed by many as the standard of care for fit patients.
Melphalan is an established alkylating drug that has demonstrated some activity in CRPC, but to date, myelosuppression has prevented adequate dosing. We have recently conducted a phase I dose escalation study using melphalan and whole blood stem cell re-infusion and it shows that median overall survival is 22 months, which is higher than the median survival rate of 19 months for Docetaxel
Data from a previous phase I study has proved the successful administration of higher doses of IV Melphalan in combination with autologous blood infusion in patients with Castration-resistant prostate cancer.
Rapid falls in circulating tumour cells were seen within 2 weeks of starting Melphalan, however slow platelet recovery meant longer periods of platelet transfusion. For this study we intend to assess the efficacy of an intensified intravenous melphalan with autologous whole blood stem cell transplantation over three treatment cycles.
39 patients will be enrolled over a 3 year period and at least 17 patients need to survive progression free at least 6-months for this study to be considered positive.
Mel-CAP is a combination chemotherapy consisting of two chemotherapy drugs:
MELPHALAN and LENOGRASTIM for 3 cycles alternately.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Contact
- Name: Jonathan Shamash, MD FRCP
- Phone Number: 02034657108
- Email: jonathan.shamash@bartshealth.nhs.uk
Study Locations
-
-
-
London, United Kingdom, EC1A 7BE
- St Batholowmew's Hospital NHS
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Men aged ≥18 years
- Histological diagnosis of prostate cancer
Progressive Castration-resistant Prostate Cancer defined as:
- a rising PSA; or
- development of new sites of disease in the presence of a suppressed testosterone (<1.5 nmol/l); or
- if testosterone >1.5 nmol/l, maximum androgen blockade failure (MAB) (MAB = GnRH analogue and peripheral anti-androgen - flutamide 250 mg 3x/day or bicalutamide 50 mg/ day or cyproterone 100mg 3x/day)
- ECOG performance status 0-2
Adequate haematological reserve:
- Unsupported Hb >9.0 g/l
- Platelets >100x109/l
- WBC >3x109/l
- Neutrophils >1.5x109/l
Renal sufficiency:
•Creatinine <200 µmol/l
Hepatic sufficiency:
- Bilirubin <30 µmol/l
- ALT <3xULN unless due to liver metastasis
- Able to give written informed consent and comply with the protocol study procedures
Exclusion Criteria:
- Patients who have suffered a previous hypersensitivity reaction to melphalan
- Patients with known hypersensitivity to lenograstim or to any of the excipients
- History of myeloid malignancy
- Lenograstim should not be administered concurrently with cytotoxic chemotherapy (i.e. on the same day)
- Previous invasive carcinoma <3 years prior to study entry
- Cardiac condition contra-indicating large volume venesection (i.e., active angina or cardiac failure)
- Current treatment with another investigational medicinal (chemotherapeutic) product or participation in another investigational therapeutic (chemotherapy)study, at any time during the treatment period and 30 days preceding study entry.
- Life expectancy <12 weeks
- Unwilling or unable to provide written informed consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Registration.
MELCAP study has only one arm. All suitable patients will receive 3 cycles of melphalan and lenograstim alternately. Patient will start with a 3 day lenograstim (at 10mcg/kg/day) to boost up the blood cell count. Upon reaching sufficient blood cell count, patients will undergo a venesection and roughly a pint of blood is taken. After this patients will receive first cycle of Melphalan (60mg/m2). The following day patient will receive back the previously given whole blood. A treament break of 6 days between the cycles is given. After the break the patient will be given Lenograstim (10mcg/kg/day)for 6 days (until sufficient). The above regimen is repeated for cycle 2 and cycle 3 with only exception of Melphalan is given at 40mg/m2. After the cycle 3, Lenograstrim is given at 263 mcg/day for 10 days. Upon treatment completion, patients will be followed for 2 years. If the patients show disease progression, they will start hormone therapy. |
Patients will receive Melphalan in three cycles In the first cycle they recieve 60mg/m2 and then 40mg/m2 in the next two cycles.
Starting Lenograstim will be at 10mcg/kg/day and between cycles at 10mcg/kgs/day. After the third cycle patient will receive 263mcg/day for 10 days. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To determine the efficacy of intensified intravenous Melphalan with autologous whole blood stem cell transplantation in patients with castration resistant prostate cancer using progression free survival.
Time Frame: 6 months progression free survival
|
6 months progression free survival
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To determine weather early falls (two weeks)in circulating tumor cells (CTC)predict the progression free survival
Time Frame: 2 weeks
|
2 weeks
|
|
To assess the changes in prostate specific antigen pre and post treament
Time Frame: 6 months
|
6 months
|
|
To study progression free survival and overall survival
Time Frame: 6 months.
|
6 months.
|
|
To assess the effect of this schedule in reintroduction of hormone senstivity
Time Frame: 6 months
|
6 months
|
|
To study the Quality of life.
Time Frame: 6 months
|
QLQ-30 and PR-25 questionnaires will be collected.
|
6 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Jonathan Shamash, MD FRCP, Barts & The London NHS Trust
Publications and helpful links
General Publications
- [1] Farrugia D, Ansell W, Singh M, Philp T, Chinegwundoh F, Oliver RT. Stilboestrol plus adrenal suppression as salvage treatment for patients failing treatment with luteinizing hormone-releasing hormone analogues and orchidectomy. BJU International 2000; 8:1069-1073. [2] Nishimura K, Nonomura N, Yasunaga Y, Takaha N, Inoue H, Sugao H, Yamaguchi S, Ukimura O, Miki T, Okuyama A. Low doses of oral dexamethasone for hormone-refractory prostate carcinoma. Cancer 2000; 15:2570-6 [3] Shamash J, Dancey G, Barlow C, Wilson P, Ansell W, Oliver RTD. Chlorambucil and lomustine (CL56) in absolute hormone refractory prostate cancer: re-induction of endocrine sensitivity an unexpected finding. British Journal of Cancer (2005) 92, 36-40 [4] Melphalan and whole blood stem cell re-infusion in the management of castration-resistant prostate cancer - J Shamash, J Jacob, T Powles, S Agrawal, K Mutsvangwa, N Saunders , P Wilson and J Stebbing [ASCO 2011] [5] Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. J Clin Oncol. 2008 Jan 10;26(2):242-5. [6] A'Hern, R. P. A. 2001. 'Sample size tables for exact single-stage phase II designs.' Statistics in Medicine, Volume 20, pages 859-866. [7] Scher H.I et al (2008). Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the prostrate cancer clinical trials working group. Journal of clinical oncology 26 (7): 1148-1159.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Genital Neoplasms, Male
- Prostatic Diseases
- Prostatic Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Adjuvants, Immunologic
- Lenograstim
- Melphalan
Other Study ID Numbers
- PR 2012 06
- 2012-000351-14 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Castrate Resistant Prostate Cancer
-
Nuvation Bio Inc.WithdrawnProstate Cancer | Prostate Neoplasm | Cancer of the Prostate | Prostatic Cancer | Castrate Resistant Prostate Cancer | Cancer of Prostate | Castration Resistant Prostatic Cancer | Castration Resistant Prostatic NeoplasmsUnited States
-
Herlev and Gentofte HospitalBristol-Myers SquibbRecruitingProstate Cancer Metastatic | Metastatic Castration-resistant Prostate Cancer | Castrate Resistant Prostate Cancer | Prostate Cancer Stage IVDenmark
-
University of Wisconsin, MadisonPfizerCompletedSolid Malignancies | Metastatic Castrate-resistant Prostate CancerUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Novartis PharmaceuticalsTerminatedProstate Cancer | Castrate Resistant Prostate Cancer | Chemotherapy Naive Prostate CancerUnited States
-
University of California, San FranciscoMerck Sharp & Dohme LLC; Prostate Cancer FoundationRecruitingProstate Cancer | Prostate Carcinoma | Metastatic Castration-resistant Prostate Cancer | Castrate Resistant Prostate CancerUnited States
-
Daniel VaenaCompletedProstate Cancer | Castrate Resistant Prostate CancerUnited States
-
AmgenCompletedCancer | Prostate Cancer | Castrate-Resistant Prostate Cancer | Mestastatic Prostate Cancer
-
IpsenTerminatedMetastatic Castrate Resistant Prostate CancerFrance, Spain, Poland, Belgium, Germany, Italy, Denmark, Lithuania, United Kingdom, Czechia, Hungary
-
Jonsson Comprehensive Cancer CenterNovartisNo longer availableProgressive Metastatic Castrate Resistant Prostate Cancer
-
British Columbia Cancer AgencyRecruitingProstate Cancer Metastatic | Metastatic Castration-resistant Prostate Cancer | Castrate Resistant Prostate CancerCanada
Clinical Trials on Melphalan
-
Hadassah Medical OrganizationUnknown
-
Uppsala UniversityDalarna County Council, Sweden; Uppsala County Council, SwedenNot yet recruitingMyeloma Multiple
-
University of California, San FranciscoTerminatedMultiple Myeloma | Patient ParticipationUnited States
-
Delcath Systems Inc.WithdrawnHepatocellular Carcinoma (HCC)United States
-
Duke UniversityCompletedLymphoma | Leukemia | Ovarian Cancer | Brain and Central Nervous System Tumors | Extragonadal Germ Cell TumorUnited States
-
Hadassah Medical OrganizationTerminated
-
University of ArizonaCompletedHematologic Neoplasms | Multiple Myeloma | Myelofibrosis | Anemia, Aplastic | Hemoglobinuria, ParoxysmalUnited States
-
Sidney Kimmel Comprehensive Cancer Center at Johns...TerminatedRetinoblastomaUnited States
-
Adherex Technologies, Inc.CompletedNeoplasmsUnited States
-
Delcath Systems Inc.Active, not recruitingBile Duct Cancer | Intrahepatic CholangiocarcinomaUnited States